Incyte (INCY) Tops Q2 EPS by 5c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 10/25/2026

1. RNG
2. DECK
3. WDC
4. BYD
5. SPOT
6. WCN
7. BMY
8. TSCO
9. BE
10. SPY

Go back to Incyte (INCY) Tops Q2 EPS by 5c

Incyte Reports 2021 Second Quarter Financial Results and Provides Updates on Key Clinical Programs

August 3, 2021 7:00 AM EDT

- Total product and royalty revenues of $696 million in Q2 2021 (+17% vs Q2 2020)

- Jakafi® (ruxolitinib) revenues of $529 million in Q2 2021 (+12% vs Q2 2020)

- Positive CHMP opinion for tafasitamab in combination with lenalidomide for the treatment of adults with relapsed or refractory diffuse large B-cell lymphoma (DLBCL)

- Phase 3 TRuE-V1 and TRuE-V2 studies evaluating ruxolitinib cream in vitiligo met primary and key secondary endpoints

Conference Call and Webcast Scheduled Today at 8:00 a.m. EDT

WILMINGTON, Del.--(BUSINESS WIRE)-- Incyte (Nasdaq: INCY)... More